Evogene Ltd. (EVGN) Form 6-K — Sep 30, 2026
Evogene received a Nasdaq letter confirming it was notified on March 30, 2026 of non-compliance with the $1.00 minimum bid price rule under Nasdaq Rule 5550(a)(2). Nasdaq granted the company an additional 180-day period, through March 29, 2027, to regain compliance; Evogene can cure the deficiency if its closing bid price is at least $1.00 for ten consecutive business days. If compliance is not achieved by March 29, 2027, Nasdaq will issue a delisting notice.
Key figures
- Extended deadline
- March 29, 2027
- Minimum bid price
- $1.00
- Original deadline
- September 28, 2026
- Compliance cure days
- 10 consecutive business days at or above $1.00
- Extension period days
- 180
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.